Location History:
- Nijmegan, NL (2015)
- Nijmegen, NL (2013 - 2023)
Company Filing History:
4 out of 16 
1 out of 4 
1 out of 1 
Years Active: 2013-2023
Title: Innovations in Cancer Treatment: The Contributions of Richard De Wijn
Introduction
Richard De Wijn, an innovative inventor based in Nijmegen, Netherlands, has made significant strides in the field of oncology through his patented methodologies. With a total of four patents to his name, De Wijn focuses on improving the treatment responses for patients diagnosed with non-small-cell lung carcinoma. His work not only contributes to medical science but also offers hope for improved patient outcomes.
Latest Patents
Among his latest innovations, Richard De Wijn has developed methods that predict the response of non-small-cell lung carcinoma patients to targeted pharmacotherapy. His patents emphasize the importance of measuring kinase-activity by studying phosphorylation levels and profiles, along with the inhibitions caused by various drugs in blood samples. These inventions provide significant advancements in understanding which specific medicaments are most effective for individual patients.
Career Highlights
Throughout his career, Richard has been associated with prestigious organizations, including Pamgene B.V. and Stichting Het Nederlands Kanker Instituut. His experience in these institutions has enabled him to contribute extensively to cancer research and treatment methodologies. The knowledge and skills he has acquired are reflected in his innovative patents, enhancing the landscape of targeted cancer therapies.
Collaborations
In his professional journey, Richard has collaborated with notable colleagues such as Robby Ruijtenbeek and Maria Helena Hilhorst. These collaborations have fostered an environment of shared expertise and innovation, furthering the development of reliable methods for predicting patient responses to cancer treatments.
Conclusion
Richard De Wijn's contributions to the field of oncology through innovative patents highlight his commitment to improving cancer care. With his focus on personalized medicine, his work is paving the way for enhanced therapeutic approaches, and it allows for better management of non-small-cell lung carcinoma in patients. As the medical community continues to adopt and refine these methods, Richard's impact on patient care will undoubtedly resonate for years to come.